New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
07:16 EDTGALEGalena Biopharma enrolls first patient in GALE-301 phase 2 trial
Galena Biopharma announced the first patient has been enrolled in the phase 2 trial for GALE-301. GALE-301 is a folate receptor alpha-derived, peptide-based cancer immunotherapy administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor as an adjuvant treatment to prevent recurrences in high-risk, endometrial and ovarian cancer patients rendered disease-free after completing standard of care therapy. The primary objective of the trial is to measure immune response, with secondary outcomes of recurrence. "With GALE-301 progressing into its Phase 2 trial, we continue to demonstrate progress of our innovative cancer immunotherapy pipeline," said Mark Ahn, president and CEO. Initial results from the Phase 1 trial determined the optimal dose and showed that GALE-301 was well tolerated and evoked a FBP specific immunological response.
News For GALE From The Last 14 Days
Check below for free stories on GALE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
07:15 EDTGALEGalena announces resignation of CEO Mark Ahn
Galena Biopharma announced that Mark Schwartz, Ph.D., has been appointed as President and CEO, effective immediately. Dr. Schwartz was previously Galena's COO. He replaces Mark Ahn, Ph.D. who has resigned as the President and CEO and as a director of the company to pursue "other long held personal and professional goals." It is expected that Dr. Schwartz will also be appointed to Galena's board.
05:32 EDTGALEGalena fired CEO over stock promotion scandal, Feuerstein says
Galena fired its CEO Mark Ahn following a stock promotion scandal, The Street's Adam Feuerstein reported last night, citing a source close to the company. A public announcement is coming today, Feuerstein added.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use